Celgene
In David Rolfe's portfolio · Wedgewood Partners
Ticker CELG
Not in the portfolio as of Q2 2026. Every quarter it shows up in a Wedgewood Partners 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q4 2019 | Sell | 0 | |
| Q3 2019 | Reduce 9% | 393,967 | 3.5% |
| Q2 2019 | Reduce 17% | 433,260 | 3.4% |
| Q1 2019 | Reduce 20% | 525,139 | 3.6% |
| Q4 2018 | Reduce 14% | 654,632 | 2.8% |
| Q3 2018 | Reduce 12% | 757,374 | 3.4% |
| Q2 2018 | Reduce 7% | 864,236 | 3.5% |
| Q1 2018 | Reduce 4% | 924,542 | 3.8% |
| Q4 2017 | Add 42% | 962,318 | 4.1% |
| Q3 2017 | Reduce 15% | 676,776 | 3.4% |
| Q2 2017 | Add 316% | 799,402 | 3.2% |
| Q1 2017 | Buy | 192,000 | 0.6% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.